ARS Pharmaceuticals, Inc. (SPRY)
3.69
+0.04
(+1.10%)
USD |
NASDAQ |
Nov 18, 16:00
3.695
0.00 (0.00%)
After-Hours: 20:00
ARS Pharmaceuticals Enterprise Value : 353.37M for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 353.37M |
| November 17, 2026 | 349.36M |
| November 16, 2026 | 343.34M |
| November 13, 2026 | 373.42M |
| November 12, 2026 | 365.40M |
| November 11, 2026 | 379.43M |
| November 10, 2026 | 341.34M |
| November 09, 2026 | 299.24M |
| November 06, 2026 | 263.15M |
| November 05, 2026 | 249.11M |
| November 04, 2026 | 289.21M |
| November 03, 2026 | 289.21M |
| November 02, 2026 | 289.21M |
| October 30, 2026 | 322.29M |
| October 29, 2026 | 350.36M |
| October 28, 2026 | 349.36M |
| October 27, 2026 | 357.38M |
| October 26, 2026 | 376.43M |
| October 23, 2026 | 387.45M |
| October 22, 2026 | 416.53M |
| October 21, 2026 | 402.49M |
| October 20, 2026 | 413.52M |
| October 19, 2026 | 407.50M |
| October 16, 2026 | 386.45M |
| October 15, 2026 | 391.46M |
| Date | Value |
|---|---|
| October 14, 2026 | 377.43M |
| October 13, 2026 | 389.46M |
| October 12, 2026 | 402.49M |
| October 09, 2026 | 407.50M |
| October 08, 2026 | 440.59M |
| October 07, 2026 | 420.54M |
| October 06, 2026 | 414.02M |
| October 05, 2026 | 413.52M |
| October 02, 2026 | 391.46M |
| October 01, 2026 | 396.48M |
| September 30, 2026 | 415.52M |
| September 29, 2026 | 390.36M |
| September 28, 2026 | 363.51M |
| September 25, 2026 | 358.54M |
| September 24, 2026 | 365.50M |
| September 23, 2026 | 368.48M |
| September 22, 2026 | 398.31M |
| September 21, 2026 | 385.39M |
| September 18, 2026 | 361.52M |
| September 17, 2026 | 365.50M |
| September 16, 2026 | 366.99M |
| September 15, 2026 | 375.44M |
| September 14, 2026 | 400.30M |
| September 11, 2026 | 426.16M |
| September 10, 2026 | 455.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Capricor Therapeutics, Inc. | 361.51M |
| Sionna Therapeutics, Inc. | -82.55M |
| Ardelyx, Inc. | 754.22M |
| Zentalis Pharmaceuticals, Inc. | -58.55M |
| Compass Therapeutics, Inc. | -43.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.59M |
| Revenue (Quarterly) | 37.71M |
| Total Expenses (Quarterly) | 73.30M |
| EPS Diluted (Quarterly) | -0.357 |
| Gross Profit Margin (Quarterly) | 73.22% |
| Profit Margin (Quarterly) | -94.37% |
| Earnings Yield | -54.54% |
| Normalized Earnings Yield | -54.54 |